Systemic Juvenile Idiopathic Arthritis (sJIA)Phase 4NCT07706868
An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
A Phase 4 study testing Anakinra (Kineret®) in people with Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still's Disease (AOSD), run by Swedish Orphan Biovitrum.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks screening, to see if a patient is suitable to the study, 48 weeks of treatment with anakinra… Read more about this study
- Who is it for?
- Ages 8 months and older
- Conditions the study is for
- Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD)
- What is being tested?
- Anakinra (Kineret®)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2025to 30 Sep 2028
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Informed consent form signed by the patient or a legal guardian representative.
- Male or female patients, 8 months of age or older with a body weight ≥ 10 kg.
- Diagnosis of Still's disease.
- Criteria for diagnosis of Still's disease:
- If < 16 years of age at disease onset, the diagnosis is made according to international league for associations of rheumatology (ILAR) criteria for SJIA.
- If ≥ 16 years of age at disease onset, the diagnosis is made according to Yamaguchi criteria for AOSD.
Show all 17Show fewer
- Active disease confirmed by the following three signs and symptoms:
- Active arthritis in ≥ 1 joint.
- CRP > 30 mg/L.
- At least one fever episode attributable to the disease within one week before enrollment.
- Definition of fever: Body temperature ≥ 38.0 °C attributable to the disease
- Background treatment with stable dose of ≤ 1 mg/kg/d (Max 60 mg/d) of oral prednisolone or equivalent for at least 3 days prior to enrollment is permitted.
- If currently on methotrexate (MTX) treatment, the dose must be stable for at least 4 weeks prior to enrollment. Maximum dose allowed is 20 mg/m2/week. If the patient discontinued MTX prior to enrollment, the discontinuation is required to be at least 4 weeks prior to enrollment.
- Female patients of childbearing potential and male patient with female partner of childbearing potential must use an effective method of contraception during the study (abstinence being a possible option). A negative pregnancy test prior to enrollment is also required.
- In case of use of oral contraception, women should have been stable on the same brand (or generic equivalent) for a minimum of 3 months before taking study treatment.
- Negative tuberculosis screening confirmed at the Screening visit by the Mantoux Tuberculin skin test (TST) using purified protein derivative (PPD), or by Interferon-Gamma-Release Assays (IGRAs) e.g., QuantiFERON® TB Gold Plus (QFT-Plus) or T¬Spot-® (TB Test) within 8 weeks prior to enrollment. Negative results must be complemented by the medical history, physical examination, and Chest X-Ray. Patients presenting positive TST or IGRA, with or without active or clinical suspicion of latent tuberculosis, are not eligible to enter the study.
- Previously vaccinated for Tuberculosis patients: IGRA positive patients are not eligible to enter the Study; TST positive patients with an induration of 15 mm and more are also not eligible to enter the study, TST positive patients (with an induration less than 15 mm) are also not eligible to enter the study, unless an IGRA test is subsequently performed and provides a negative result.
Who cannot join
- Previous enrollment to this study
- Participation in another clinical interventional study 30 days prior to enrollment.
- Treatment with an investigational drug within 5 half-lives prior to enrollment.
- Previous or current treatment with anakinra, or any other IL-1 inhibitor, except for canakinumab. Previous treatment with canakinumab is allowed if canakinumab was discontinued for reasons other than lack of efficacy and after a washout period of minimum 130 days (Refer to Exclusion Criteria 5). Patients who have discontinued canakinumab because of insufficient effect, refractory disease or toxicities are not allowed to be enrolled in the study.
- Use of the following therapies prior to enrollment:
- Narcotic analgesics within 24 hours prior to enrollment.
Show all 28Show fewer
- Dapsone within 1 week prior to enrollment or etanercept within 2 weeks prior to enrollment.
- Intraarticular, intramuscular, or intravenous administration of glucocorticoids within 72h (3 days) prior to enrollment, or intravenous immunoglobulin within 4 weeks prior to enrollment.
- Leflunomide, infliximab or adalimumab within 8 weeks prior to enrollment.
- Thalidomide within 72h (3 days) prior to enrollment, cyclosporine within 5 weeks prior to enrollment, tacrolimus hydrate within 2 weeks prior to enrollment, mycophenolate mofetil within 1 week prior to enrollment, 6-mercaptopurine within 48h (2 days) prior to enrollment, azathioprine within 72h (3 days) prior to enrollment, cyclophosphamide within 96h (4 days) prior to enrollment, chlorambucil within 48h (2 days) prior to enrollment, Janus kinase (JAK) inhibitors within 5 half-lives prior to enrollment, or any other immunosuppressant within 12 weeks prior to enrollment.
- Tocilizumab within 4 weeks prior to enrollment or any other immunomodulatory medication within 5 half-lives prior to enrollment.
- Rituximab within 26 weeks prior to enrollment.
- Canakinumab within 130 days prior to enrollment.
- Live vaccines within 4 weeks prior to enrollment.
- Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection, coronavirus disease (Covid-19) infection, hepatitis B or C infection at baseline.
- Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN), or
- AST or ALT > 3 x ULN and elevated bilirubin > 2 x ULN.
- Presence of severe chronic kidney disease (CKD) stages 4 and 5 (estimated creatinine clearance < 30 mL/min/1.73m2).
- Presence of neutropenia (ANC < 1.5 x 109/L).
- Presence of thrombocytopenia (platelets count < 100 x 109/L).
- Presence or suspicion of macrophage activation syndrome (MAS) at baseline.
- A diagnosis of macrophage activation syndrome (MAS) within the last 2 months prior to enrollment.
- History of malignancy within 5 years prior to enrollment. Exceptions are basal cell skin cancer, carcinoma-in-situ of the cervix, or low-risk prostate cancer after curative therapy.
- Known hypersensitivity to E. Coli-derived proteins, or any components of anakinra.
- Pregnant or lactating women.
- Foreseeable inability to cooperate with given instructions or study procedures.
- Presence of any medical, psychological condition, or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements, or make the patient not appropriate for inclusion to the study and treatment with IMP.
About this study
Official title: A Prospective, Open-label, Multicenter, Post-authorization, Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks screening, to see if a patient is suitable to the study, 48 weeks of treatment with anakinra and 4 weeks safety follow up after last dose of anakinra. In total 60 patients(expected allocation is 30 SJIA and 30 AOSD), male or female patients, 8 months of age or older with a body weight ≥ 10 kg, will be enrolled to the study.
Read the detailed description
This is a prospective, open-label, multicenter, efficacy and safety study of anakinra in Chinese patients with Still's disease (SJIA and AOSD). The study consists of a 48-Week treatment period with anakinra followed by a 4-Week period to evaluate safety of anakinra after the last dose of IMP. The study is divided into three parts: screening, treatment period, and safety follow-up, and will be performed in China.
The study will recruit a total of 60 patients (expected allocation is 30 SJIA and 30 AOSD).
The patient will enter screening after informed consent is obtained and will undergo screening assessments to confirm eligibility. Duration of the screening period will be kept as short as possible and should not exceed 4 weeks.
Patients will be assigned to study drug after they have met all of the inclusion criteria and none of the exclusion criteria. Patients will receive treatment with anakinra for 48 weeks.
After the last dose of anakinra at Week 48, the safety will continue to be evaluated at a Safety Follow-up visit i.e., at Week 52.
14 visits and 1 telephone contact are scheduled during the study as follows: Screening visit (Visit 0), Day 1 (Baseline visit), Day 4Tel, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48 (last dose of anakinra), and Week 52 (end of study).
All patients included in the study will be carefully monitored by the investigator. Patients can withdraw from the study drug at any time for any reason. If a patient permanently discontinues study drug, at any time during the study prior to week 48, a Study Drug Discontinuation visit should be performed, if possible before standard of care treatment is initiated. If clinically not feasible, the Study Drug Discontinuation visit should be performed as soon as possible.
4 weeks after discontinuation of study drug, a subsequent Safety Follow-up visit will be performed, according to the assessments described for the Week 52 visit, after which the patient will be withdrawn from the study.
- Being tested
- Anakinra (Kineret®)
- Medical subject headings
- Arthritis, Juvenile, Still's Disease, Adult-Onset
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anakinra (Kineret®)Drug
Subcutaneous injections once daily for 48 weeks
| Study group | Role | What they receive |
|---|---|---|
| Anakinra | Experimental | Anakinra, once daily s.c. injection, starting dose of 100 mg/day for patients with body weight ≥ 50 kg and 1-2 mg/kg/day for patients with body weight < 50 kg.
Pediatric and adult patients weighing ≥ 50kg will receive 100 mg anakinra per day by subcutaneous injection.
Pediatric and adult patients weighing < 50 kg should be dosed by body weight with a starting dose of anakinra of 1 to 2 mg/kg/day (with a max of 100 mg/day). If patients receiving 1 mg/kg/d are not responding at Week 1, the dose will be escalated to 2 mg/kg/day.
If at the appreciation of the investigator, a patient < 16 years old with a body weight below 50 kg, is not responding sufficiently to anakinra treatment at Week 4 visit, the dose will be adjusted according to actual body weight (rounded to the nearest kg) and will be increased up to 4 mg/kg/day with a max of 200 mg/day or the continuation of anakinra will be considered by the investigator. Receives: Drug: Anakinra (Kineret®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
ACR30 response at Week 4 with absence of fever attributable to the disease during the 7 days preceding Week 4 visit.
Definition of American College of Rheumatology (ACR) 30 response in SJIA and AOSD patients: An improvement of ≥ 30% from baseline to Week 4 visit, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%. 1. Physician global assessment of disease activity (visual analogue scale [VAS]). 2. Patient/parent global assessment of overall well-being (VAS). 3. Number of joints with active arthritis. 4. Number of joints with limitation of motion. 5. Assessment of physical function (Child health assessment questionnaire [CHAQ]/ Stanford health assessment questionnaire [SHAQ]). 6. CRP (mg/L). Definition of fever: Body temperature ≥ 38.0 °C attributable to the disease. Definition of active arthritis: Joint with swelling. In absence of swelling, limitation of range of motion accompanied by either pain on motion or tenderness not due to deformity.
Measured: Up to 48 weeks.
Secondary outcomes (24)
Absence of fever during the 7 days preceding week 4.
Measured: Up to week 48.
Absence of rash during the 7 days preceding Week 4.
Measured: Up to week 48.
ACR50, ACR70, and ACR90 response with absence of fever during the 7 days preceding Week 4.
Measured: Up to week 48.
Absence of fever during the 7 days preceding each visit.
Measured: Up to week 48.
Absence of rash during the 7 days preceding each visit.
Measured: Up to week 48.
ACR30 response with absence of fever during the 7 days preceding each visit.
Definition of ACR30 response in SJIA and AOSD patients:
An improvement of ≥ 30%, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%, and no intermittent fever attributable to the disease during the preceding 7 days.
Measured: Up to week 48.
ACR50 response with absence of fever during the 7 days preceding each visit.
Definition of ACR50 response in SJIA and AOSD patients:
An improvement of ≥ 50%, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%, and no intermittent fever attributable to the disease during the preceding 7 days.
Measured: Up to week 48.
ACR70 response with absence of fever during the 7 days preceding each visit.
Definition of ACR70 response in SJIA and AOSD patients:
An improvement of ≥ 70% in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%, and no intermittent fever attributable to the disease during the preceding 7 days.
Measured: Up to week 48.
ACR90 response with absence of fever during the 7 days preceding each visit.
Definition of ACR90 response in SJIA and AOSD patients:
An improvement of ≥ 90% in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%, and no intermittent fever attributable to the disease during the preceding 7 days.
Measured: Up to week 48.
Change from baseline in physician global assessment of disease activity (VAS).
Measured: Up to week 48.
Change from baseline in patient/parent global assessment of overall well-being (VAS).
Measured: Up to week 48.
Change from baseline in C-reactive protein (CRP) concentrations.
CRP levels (measured in mg/L) will be determined in serum.
Measured: Up to week 48.
Change from baseline in ferritin concentrations.
Ferritin levels (measured in ng/ml) will be determined in serum.
Measured: Up to week 48.
Change from white blood cell counts.
White blood cell counts (measured in cells per μL) will be determined in serum.
Measured: Up to week 48.
Occurrence of inactive disease
Proportion of patients who reach inactive disease at Week 8 and at the following respective visits up to Week 48.
Measured: Up to week 48.
Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), deaths, and AEs leading to study drug discontinuation
An AE is any untoward medical occurrence in a study patient to whom a medicinal product is administered, and which does not necessarily have a causal relationship with this treatment.
AEs include abnormal test findings, clinically significant signs and symptoms, changes in physical examination findings, progression or worsening of underlying disease.
Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.
Measured: Up to week 52.
Changes over time in blood pressure
Blood pressure (mmHg) change of each patient are evaluated over time.
Measured: Up to week 48.
Changes over time in heart rate
Heart rate (beats per minute) change of each patient are evaluated over time.
Measured: Up to week 48.
Changes over time in body temperature
Body temperature (Celsius degrees) change of each patient are evaluated over time.
Measured: Up to week 48.
Changes over time in body weight
Body weight (kilograms) for all patients are evaluated over time.
Measured: Up to week 48.
Changes over time in height
Height (centimeters) are evaluated over time for pediatric patients
Measured: Up to week 48.
Changes over time in Laboratory safety assessment
Measured: Up to week 48.
Number of patients with abnormal laboratory values
Measured: Up to week 48.
Evaluation of the pharmacokinetic of anakinra in patients with Still's disease.
Anakinra serum concentration at Baseline, Week 2 and Week 4 visits.
Measured: Up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start1 Sep 2025 (estimated)
- Primary completion30 Sep 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Why it stopped: Business decision
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Juvenile Idiopathic Arthritis (sJIA)Studies of the same condition, open and under way.
- More trials run by Swedish Orphan BiovitrumThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Swedish Orphan Biovitrum
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Tigermed Consulting Co., Ltd
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07706868
- Sponsor's protocol ID
- Sobi.ANAKIN-304
- Status last verified
- Jun 2026
- First submitted
- 24 Jun 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-label, Multicenter, Post-authorization, Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
- ClinicalTrials.gov ID
- NCT07706868
- Acronym / sponsor ID
- Sobi.ANAKIN-304
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Business decision
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Swedish Orphan BiovitrumIndustry (pharma, biotech, devices)
- Collaborators
- Tigermed Consulting Co., Ltd
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- 30 Sep 2028 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks screening, to see if a patient is suitable to the study, 48 weeks of treatment with anakinra and 4 weeks safety follow up after last dose of anakinra. In total 60 patients(expected allocation is 30 SJIA and 30 AOSD), male or female patients, 8 months of age or older with a body weight ≥ 10 kg, will be enrolled to the study.
Detailed description
This is a prospective, open-label, multicenter, efficacy and safety study of anakinra in Chinese patients with Still's disease (SJIA and AOSD). The study consists of a 48-Week treatment period with anakinra followed by a 4-Week period to evaluate safety of anakinra after the last dose of IMP. The study is divided into three parts: screening, treatment period, and safety follow-up, and will be performed in China.
The study will recruit a total of 60 patients (expected allocation is 30 SJIA and 30 AOSD).
The patient will enter screening after informed consent is obtained and will undergo screening assessments to confirm eligibility. Duration of the screening period will be kept as short as possible and should not exceed 4 weeks.
Patients will be assigned to study drug after they have met all of the inclusion criteria and none of the exclusion criteria. Patients will receive treatment with anakinra for 48 weeks.
After the last dose of anakinra at Week 48, the safety will continue to be evaluated at a Safety Follow-up visit i.e., at Week 52.
14 visits and 1 telephone contact are scheduled during the study as follows: Screening visit (Visit 0), Day 1 (Baseline visit), Day 4Tel, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48 (last dose of anakinra), and Week 52 (end of study).
All patients included in the study will be carefully monitored by the investigator. Patients can withdraw from the study drug at any time for any reason. If a patient permanently discontinues study drug, at any time during the study prior to week 48, a Study Drug Discontinuation visit should be performed, if possible before standard of care treatment is initiated. If clinically not feasible, the Study Drug Discontinuation visit should be performed as soon as possible.
4 weeks after discontinuation of study drug, a subsequent Safety Follow-up visit will be performed, according to the assessments described for the Week 52 visit, after which the patient will be withdrawn from the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Anakinra | Experimental | Drug: Anakinra (Kineret®)Anakinra, once daily s.c. injection, starting dose of 100 mg/day for patients with body weight ≥ 50 kg and 1-2 mg/kg/day for patients with body weight < 50 kg. Pediatric and adult patients weighing ≥ 50kg will receive 100 mg anakinra per day by subcutaneous injection. Pediatric and adult patients weighing < 50 kg should be dosed by body weight with a starting dose of anakinra of 1 to 2 mg/kg/day (with a max of 100 mg/day). If patients receiving 1 mg/kg/d are not responding at Week 1, the dose will be escalated to 2 mg/kg/day. If at the appreciation of the investigator, a patient < 16 years old with a body weight below 50 kg, is not responding sufficiently to anakinra treatment at Week 4 visit, the dose will be adjusted according to actual body weight (rounded to the nearest kg) and will be increased up to 4 mg/kg/day with a max of 200 mg/day or the continuation of anakinra will be considered by the investigator. |
Who may qualify
- Ages
- 8 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (17 listed)
- Informed consent form signed by the patient or a legal guardian representative.
- Male or female patients, 8 months of age or older with a body weight ≥ 10 kg.
- Diagnosis of Still's disease.
- Criteria for diagnosis of Still's disease:
- Active disease confirmed by the following three signs and symptoms:
Key exclusion criteria (28 listed)
- Previous enrollment to this study
- Participation in another clinical interventional study 30 days prior to enrollment.
- Treatment with an investigational drug within 5 half-lives prior to enrollment.
- Previous or current treatment with anakinra, or any other IL-1 inhibitor, except for canakinumab. Previous treatment with canakinumab is allowed if canakinumab was discontinued for reasons other than lack of efficacy and after a washout period of minimum 130 days (Refer to Exclusion Criteria 5). Patients who have discontinued canakinumab because of insufficient effect, refractory disease or toxicities are not allowed to be enrolled in the study.
- Use of the following therapies prior to enrollment:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anakinra (Kineret®)Subcutaneous injections once daily for 48 weeks | Drug | Anakinra |
Primary outcome
ACR30 response at Week 4 with absence of fever attributable to the disease during the 7 days preceding Week 4 visit.
Time frame: Up to 48 weeks.
Definition of American College of Rheumatology (ACR) 30 response in SJIA and AOSD patients: An improvement of ≥ 30% from baseline to Week 4 visit, in at least 3 of any 6 variables of the ACR core set listed below, with no more than 1 variable worsening by > 30%. 1. Physician global assessment of disease activity (visual analogue scale [VAS]). 2. Patient/parent global assessment of overall well-being (VAS). 3. Number of joints with active arthritis. 4. Number of joints with limitation of motion. 5. Assessment of physical function (Child health assessment questionnaire [CHAQ]/ Stanford health assessment questionnaire [SHAQ]). 6. CRP (mg/L). Definition of fever: Body temperature ≥ 38.0 °C attributable to the disease. Definition of active arthritis: Joint with swelling. In absence of swelling, limitation of range of motion accompanied by either pain on motion or tenderness not due to deformity.
24 secondary outcomes
Absence of fever during the 7 days preceding week 4.
Time frame: Up to week 48.
Absence of rash during the 7 days preceding Week 4.
Time frame: Up to week 48.
ACR50, ACR70, and ACR90 response with absence of fever during the 7 days preceding Week 4.
Time frame: Up to week 48.
Absence of fever during the 7 days preceding each visit.
Time frame: Up to week 48.
Absence of rash during the 7 days preceding each visit.
Time frame: Up to week 48.
ACR30 response with absence of fever during the 7 days preceding each visit.
Time frame: Up to week 48.
ACR50 response with absence of fever during the 7 days preceding each visit.
Time frame: Up to week 48.
ACR70 response with absence of fever during the 7 days preceding each visit.
Time frame: Up to week 48.
ACR90 response with absence of fever during the 7 days preceding each visit.
Time frame: Up to week 48.
Change from baseline in physician global assessment of disease activity (VAS).
Time frame: Up to week 48.
Change from baseline in patient/parent global assessment of overall well-being (VAS).
Time frame: Up to week 48.
Change from baseline in C-reactive protein (CRP) concentrations.
Time frame: Up to week 48.
Change from baseline in ferritin concentrations.
Time frame: Up to week 48.
Change from white blood cell counts.
Time frame: Up to week 48.
Occurrence of inactive disease
Time frame: Up to week 48.
Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), deaths, and AEs leading to study drug discontinuation
Time frame: Up to week 52.
Changes over time in blood pressure
Time frame: Up to week 48.
Changes over time in heart rate
Time frame: Up to week 48.
Changes over time in body temperature
Time frame: Up to week 48.
Changes over time in body weight
Time frame: Up to week 48.
Changes over time in height
Time frame: Up to week 48.
Changes over time in Laboratory safety assessment
Time frame: Up to week 48.
Number of patients with abnormal laboratory values
Time frame: Up to week 48.
Evaluation of the pharmacokinetic of anakinra in patients with Still's disease.
Time frame: Up to 4 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Systemic Juvenile Idiopathic Arthritis (sJIA)
RecruitingObservational study
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Still's Disease, Adult-Onset, Systemic Inflammation
Not yet recruitingObservational study
Pulmonary Involvement in Children With Systemic JIA
Systemic Juvenile Idiopathic Arthritis, Lung Diseases
RecruitingPhase 2
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Juvenile Idiopathic Arthritis
RecruitingObservational study
Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis
RecruitingPhase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Still´s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Anakinra (Kineret®) in people with Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still's Disease (AOSD), run by Swedish Orphan Biovitrum.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ACR30 response at Week 4 with absence of fever attributable to the disease during the 7 days preceding Week 4 visit. (time frame: Up to 48 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.